Chemical Data :
Molecular Weight: 368.16 g/mol
Molecular Formula: C20H21FN4O2
AB FUBINACA Profile
AB FUBINACA is a psychoactive drug compound and potent and full agonist at the human cannabinoid receptor CB1. It is classed as a synthetic cannabinoid.
AB FUBINACA was originally developed by a team of chemists at the pharmaceutical giant Pfizer whilst investigating synthetic cannabinoids as potential analgesic medicines. It was never pursued by the company for medical use likely owing to the range pronounced side effects it produces in addition to pain relief. Subsequently it has been discovered in synthetic cannabis preparations collected by authorities in Japan.The chemical use is linked with fatalities and hospitalisations.
The chemical has the formal and systematic IUPAC name (N-[(1S)-1-(Aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide), a molar mass of 368.4 grams and empirical formula C20H21FN4O2.
Ligand binding assay experiments have determined that the chemical binds at CB1 with a ki of 0.9 nM and at CB2 with a Ki of 23.2 nM. It has an EC50 at CB1 IN 1.8 nM and at CB2 the EC50 value is 3.2 nM.
The chemical belongs to the indazole class of substituted cannabinoids. A para substituted fluorophenyl is bond to the indazole core at R1 via a methyl bridge. At R3 the indazole is substituted with a carboxamide which is in turn bonded to a L-Valinamide moiety by N-terminal substitution.
The action of AB-FUBINACA at CB1 receptors as full agonist is in contrast to the action of THC as a partial agonist at CB1. THC is the primary psychoactive constituent of herbal marijuana. AB-FUBINACA in contrast to marijuana has much more potent effects on the mind and body compared to traditional herbal marijuana. In fact the action of AB-FUBINACA can be debilitating and may lead to seizures, coma and hospitalisations. It is the full agonist ability of these compounds which means users are at risk of overdose unlike marijuana which has caused no deaths despite a long history of use.
The health implications of short term or long term recreational use of AB-FUBINACA are not known. There have been no scientific studies in to the toxicology of this compound in humans.
The fluorinated synthetic cannabinoids have high boiling points in excess of 500 oC. Their thermal decomposition takes place below their boiling point. Breakdown products will include highly reactive and toxic fluorocarbons which the user may inhale causing potentially deleterious effects on the lungs and systemic organ systems such as the brain. It is for this reason that if these chemicals are to be consumed it is safest by a cold process. A cold process is any delivery method which does not involve heat for example oral, rectal or ultrasonic nebulisation. Hot delivery methods include smoking and thermal vaporisation. Virtually all e-cigarettes produce their vapour by thermal means. Therefore to be safe one should not use a traditional e-cigarette but an ultrasonic nebuliser or choose one of the non-fluorinated cannabinoids.
AB-FUBINACA is not fit for human or animal consumption.
Unverifiable online reports claim it has a very strong sedating cannabis like effect in humans.
Use of synthetic cannabinoids like AB-FUBINACA may lead to addiction.
Other names and synonyms for AB-Fubinaca:
1H-Indazole-3-carboxamide, N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]- [ACD/Index Name]
N-[(2S)-1-Amino-3-methyl-1-oxo-2-butanyl]-1-(4-fluorbenzyl)-1H-indazol-3-carboxamid [German] [ACD/IUPAC Name]
N-[(2S)-1-Amino-3-methyl-1-oxo-2-butanyl]-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide [ACD/IUPAC Name]
N-[(2S)-1-Amino-3-méthyl-1-oxo-2-butanyl]-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide [French] [ACD/IUPAC Name]
AB- FUBINACA (exempt preparation)
AB-FUBINACA (exempt preparation)